PMS2

PMS2
Emw · CC BY-SA 3.0 · source
Name	PMS2 homolog 2, mismatch repair system component
Altsymbols	PMS2A, Pms2
Location	7p22
Omim	600259
Uniprot	P54278

PMS2

PMS2 is a human gene encoding a protein central to post-replicative DNA mismatch repair. It forms a heterodimeric complex with an MLH family ATPase to recognize and process base–base mismatches and insertion–deletion loops, contributing to genomic stability and tumor suppression. Germline and somatic alterations of the gene are implicated in hereditary cancer predisposition and sporadic neoplasia across multiple tissues.

Introduction

PMS2 was first characterized in studies of eukaryotic mismatch repair alongside discoveries by researchers working on Saccharomyces cerevisiae, Escherichia coli, and mammalian cell systems. Historical work by investigators at institutions such as Cold Spring Harbor Laboratory and Howard Hughes Medical Institute contributed to identifying the MLH family and its partners. Insights from clinical cohorts at centers including Mayo Clinic, Johns Hopkins Hospital, and MD Anderson Cancer Center linked defects in the gene to hereditary cancer syndromes and informed clinical guidelines from bodies like the National Comprehensive Cancer Network and public health agencies.

Gene and Protein Structure

The gene maps to the short arm of chromosome 7 at 7p22 and spans multiple exons; genomic annotation has been refined by consortia including the Human Genome Project and the Ensembl and UCSC Genome Browser projects. The encoded protein is a 5′→3′ ATPase-related factor belonging to the MutL homolog family; structural studies have leveraged techniques from groups at the European Molecular Biology Laboratory and Max Planck Society to resolve domains by X-ray crystallography and cryo-electron microscopy. Key motifs include an N-terminal ATP-binding site and a C-terminal interaction interface that mediates heterodimerization with MLH family members characterized by teams at Cold Spring Harbor Laboratory and Massachusetts Institute of Technology. Alternative splicing and polymorphic sites cataloged by the 1000 Genomes Project and ClinVar contribute to allelic diversity.

Function in DNA Mismatch Repair

Functionally, the protein partners with an MLH ATPase to form a complex that couples mismatch recognition by MutS homologs—identified in work from Stanford University and University of California, Berkeley—to downstream excision and resynthesis pathways studied by researchers at National Institutes of Health laboratories. The complex interacts with replication factor C and proliferating cell nuclear antigen, concepts elucidated in experiments from European Molecular Biology Laboratory groups and clinical labs at Cambridge University Hospitals. Biochemical assays developed by teams at Cold Spring Harbor Laboratory and Max Planck Institute show ATP hydrolysis–dependent conformational changes regulate strand discrimination and endonucleolytic activation, a mechanism further refined in mechanistic studies published from Harvard Medical School and UCSF investigators.

Clinical Significance and Associated Disorders

Germline pathogenic variants were associated with Lynch syndrome in landmark studies involving cohorts from University of Southern California, Vanderbilt University Medical Center, and University of Toronto, shaping screening efforts recommended by United States Preventive Services Task Force–level guideline committees and cancer networks such as the European Society for Medical Oncology. Carriers exhibit increased risks for colorectal cancer, endometrial cancer, and other malignancies; genotype–phenotype correlations have been explored in registries managed by Prospective Lynch Syndrome Database contributors and international consortia headquartered at St. Mark's Hospital. Biallelic deleterious variants cause a distinct childhood-onset condition first described by clinicians at Great Ormond Street Hospital and characterized in case series from Boston Children's Hospital and Hospices Civils de Lyon, presenting with early-onset malignancies, hematologic abnormalities, and neurological features. Somatic loss through promoter methylation or large genomic rearrangements has been studied in tumor profiling projects such as The Cancer Genome Atlas and informs biomarker status for immune checkpoint therapies evaluated in trials coordinated by groups at National Cancer Institute and European Organisation for Research and Treatment of Cancer.

Diagnostic Testing and Genetic Counseling

Clinical testing approaches developed by laboratories affiliated with Mayo Clinic Laboratories, Invitae, and academic centers use germline sequencing, multiplex ligation-dependent probe amplification, and transcript analysis to detect point variants and structural changes cataloged in databases like ClinVar and LOVD. Tumor-based assays, including immunohistochemistry panels standardized by pathology societies at Royal College of Pathologists and microsatellite instability testing advanced in studies from Memorial Sloan Kettering Cancer Center, guide reflex germline evaluation. Genetic counseling frameworks from organizations such as the American College of Medical Genetics and Genomics and European Society of Human Genetics address variant interpretation, cascade testing, reproductive options, and surveillance protocols implemented at centers like Cleveland Clinic and Guy's and St Thomas' NHS Foundation Trust.

Research, Therapeutic Implications, and Model Systems

Ongoing research employs engineered models from laboratories at Broad Institute and Sanger Institute, including CRISPR-edited cell lines and mouse models developed at Jackson Laboratory to study mutator phenotypes and tumorigenesis. Preclinical and clinical studies of immune checkpoint inhibitors in mismatch repair–deficient tumors have been led by teams at MD Anderson Cancer Center and Dana-Farber Cancer Institute, influencing regulatory decisions by agencies such as the Food and Drug Administration and European Medicines Agency. Drug discovery efforts targeting synthetic lethal interactions and exploiting replication stress involve collaborations with industry partners like Genentech and AstraZeneca and academic translational hubs at Cambridge Biomedical Campus. International consortia, for example those coordinated through InSiGHT and the Lynch Syndrome International Study Group, continue to refine risk estimates, natural history, and precision prevention strategies.

Category:DNA repair genes